Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...

Drug Regulation

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...

Drug Products: Biologics, Biosimilars and Interchangeables

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

Modified-Release Drug Delivery Systems: Influencing Factors

Modified-Release Drug Delivery Systems: Influencing Factors

Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...

Drug Administration and Therapy Phases: Overview

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Delirium in patients with advanced cancer.

The Lancet. Oncology·2016

Same author

THE RISE OF THE CHIEF EXPERIENCE OFFICER.

Physician leadership journal·2015

Same author

Road To Developing Regulatory Pathway For Biologic Follow-ons Has Many Turns.

Biotechnology healthcare·2013

Same author

Approvals, FDA actions, clinical trials.

Biotechnology healthcare·2013

Same author

HCV testing cost-effective alternative to treating advanced disease.

Biotechnology healthcare·2013

Same author

Approvals, FDA actions, clinical trials.

Biotechnology healthcare·2013

Same journal

Big pharma moves into biologics.

Biotechnology healthcare·2013

Same journal

Study: High Copayments Cut Biodrug Use up to 21 Percent.

Biotechnology healthcare·2013

Same journal

Avian flu and the quest for immunity: not just chicken feed.

Biotechnology healthcare·2013

Same journal

Variety of Biotech Therapies, Uses Take Prominence Among ASCO Presentations.

Biotechnology healthcare·2013

Same journal

Opening the door to follow-on proteins?

Biotechnology healthcare·2013

Same journal

On specialty pharmaceuticals: reflections of a second-year medical student.

Biotechnology healthcare·2013

See all related articles

Search research articles

Related Experiment Video

Updated: May 14, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

FDA: Change Is Good.

Biotechnology Healthcare

|February 2, 2013

Summary

This summary is machine-generated.

The U.S. Food and Drug Administration (FDA) moved biologic drug oversight to its drug-evaluation center. This change is praised, but its impact on review efficiency and costs remains to be seen.

More Related Videos

Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor

Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor

Published on: August 18, 2023

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Related Experiment Videos

Last Updated: May 14, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor

Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor

Published on: August 18, 2023

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Area of Science:

Pharmacology
Drug Regulation
Biotechnology

Background:

Biologic medications represent a significant and growing class of therapeutic agents.
Historically, oversight of biologics and small-molecule drugs has been managed by different centers within the FDA.
Recent organizational changes aim to centralize the evaluation of most biologic products.

Purpose of the Study:

To evaluate the recent transfer of oversight for most biologic medications to the FDA's Center for Drug Evaluation and Research (CDER).
To assess the initial reception and potential implications of this regulatory consolidation.

Main Methods:

Analysis of regulatory policy changes regarding biologic drug oversight.
Review of expert opinions and initial commentary on the FDA's organizational shift.
Monitoring of key performance indicators related to drug review timelines and costs (longitudinal observation).

Main Results:

The transfer of oversight has been met with initial praise from stakeholders.
The long-term effects on reducing review times and associated costs are currently undetermined.

Conclusions:

The consolidation of biologic oversight under CDER is a notable regulatory development.
Further data collection and analysis are required to ascertain the ultimate success of this initiative in improving efficiency and cost-effectiveness.